Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis

Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis

Published

News published by Avalyn Pharma concerning AP02 (inhaled nintedanib), administered via an optimized eFlow® Technology nebulizer.
 

Read the press release

Back to overview